Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients

NCT01730404 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: CHF6001 DPI
DRUG: Roflumilast
DRUG: Placebo

Sponsor

Chiesi Farmaceutici S.p.A.